GSK-3β Is Required for Memory Reconsolidation in Adult Brain by Kimura, Tetsuya et al.
GSK-3b Is Required for Memory Reconsolidation in Adult
Brain
Tetsuya Kimura, Shunji Yamashita, Shinobu Nakao, Jung-Mi Park, Miyuki Murayama, Tatsuya Mizoroki,
Yuji Yoshiike, Naruhiko Sahara, Akihiko Takashima*
Lab for Alzheimer’s Disease, RIKEN Brain Science Institute, Wako, Saitama, Japan
Abstract
Activation of GSK-3b is presumed to be involved in various neurodegenerative diseases, including Alzheimer’s disease (AD),
which is characterized by memory disturbances during early stages of the disease. The normal function of GSK-3b in adult
brain is not well understood. Here, we analyzed the ability of heterozygote GSK-3b knockout (GSK+/2) mice to form
memories. In the Morris water maze (MWM), learning and memory performance of GSK+/2 mice was no different from that
of wild-type (WT) mice for the first 3 days of training. With continued learning on subsequent days, however, retrograde
amnesia was induced in GSK+/2 mice, suggesting that GSK+/2 mice might be impaired in their ability to form long-term
memories. In contextual fear conditioning (CFC), context memory was normally consolidated in GSK+/2 mice, but once the
original memory was reactivated, they showed reduced freezing, suggesting that GSK+/2 mice had impaired memory
reconsolidation. Biochemical analysis showed that GSK-3b was activated after memory reactivation in WT mice.
Intraperitoneal injection of a GSK-3 inhibitor before memory reactivation impaired memory reconsolidation in WT mice.
These results suggest that memory reconsolidation requires activation of GSK-3b in the adult brain.
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Introduction
Two GSK-3 isoforms (a and b) are encoded by different genes
in mammalian tissues [1]. GSK-3b is highly enriched in the brain,
where it phosphorylates metabolic enzymes, signal proteins,
structural proteins, and transcription factors [2–4]. GSK-3b is a
constitutively active kinase. Most GSK-3b substrates are under
negative regulation, which is relieved by Ser9 phosphorylation
through other kinases such as PKC, PKA, and Akt [3]. GSK-3
inhibitor experiments suggest that GSK-3 may be involved in
mood disorders, schizophrenia, and pathogenesis of neurofibrillary
tangles (NFTs) [4–7].
NFTs, neuropathological hallmarks of neurodegenerative disor-
ders, are composed of highly phosphorylated tau [8–10]. GSK-3b is
an enzyme potentially involved in forming highly phosphorylated
tau in NFTs [11–14]. This hypothesis is supported by the
observation that a GSK-3 inhibitor prevents NFT formation in an
animal model [4,15]. Aggregated Ab activates GSK-3b and induces
hyperphosphorylation of tau and neuronal death [14,16,17].
Furthermore, the overexpression of GSK-3b affects spatial memory
and accelerates NFT formation in a mouse model [18,19]. This
accumulating evidence suggests that activation of GSK-3b may be
involved in NFT formation and neuronal loss in neurodegenerative
diseases, including Alzheimer’s disease (AD).
One hypothesis explaining the role of GSK-3b in the adult
brain posits that under normal conditions, GSK-3b is inhibited
and does not affect brain function. However, in disease states,
GSK-3b becomes activated through the elimination of inactiva-
tion signals, leading to neurodegeneration. This hypothesis
provides the basis for the development of GSK-3b inhibitors as
potential therapeutic drugs for treating AD and other neurode-
generative diseases. However, it is inconceivable that a constitu-
tively active kinase such as GSK-3b exists for the purpose of
neurodegeneration.
Recently, Peineau et al. [20] reported the importance of GSK-
3b activity during the induction of long term depression (LTD),
suggesting that GSK-3b activity may contribute to the control of
synaptic plasticity and memory function. If GSK-3b is involved
only in neurodegeneration, then a genetic reduction of GSK-3b
would not be expected to affect cognitive function. On the other
hand, if GSK-3b is involved in normal brain function, a genetic
reduction of GSK-3b would be expected to affect cognitive
function. To test this hypothesis, we compared memory formation
and maintenance of heterozygous GSK-3b gene-deficient mice
(GSK
+/2) and their wild-type (WT) littermates using the Morris
water maze (MWM) test and a contextual fear-conditioning (CFC)
test. GSK
+/2 mice lacked the ability to maintain memory after
recall, suggesting GSK-3b importantly contributes to memory
maintenance after recall in normal brains.
Results
Generation and characterization of GSK
+/2
To understand the normal role of GSK-3b in the adult brain,
we generated GSK-3b gene-deficient mice according to published
methods [21] and analyzed heterozygous GSK-3b gene-deficient
PLoS ONE | www.plosone.org 1 October 2008 | Volume 3 | Issue 10 | e3540(GSK
+/2) mice. The total amount of GSK-3b in GSK
+/2 mice
was approximately 50% of that in WT littermate mice, whereas
the relative activity of GSK-3b in GSK
+/2 mice was about 70% of
that in WT littermates (see Supporting information Fig. S1). As
previously reported [21], GSK
+/2 mice were healthy, fertile, had
normal circadian rhythms and life span, but had unimpaired
motor and locomotor activity compared to their WT littermates
(see Supporting information Fig. S2). This was the case even
though they had reduced GSK-3b activity and lacked GSK-3a
compensation (see Supporting information Fig. S1).
GSK
+/2 mice exhibited retrograde amnesia with repeated
training in MWM
Adult mice (7–14 months old) were trained 3 times a day to find
a fixed but hidden platform submerged in a circular pool; training
occurred for 3 or 9 days. Memory performance was measured in
terms of an error score, which represents the cumulative distance a
mouse traveled in each trial as it searched to find the hidden
platform. The error score more accurately and sensitively reflects a
mouse’s place preference in a trial than other parameters
(Supporting information Fig. S3). Fig. 1A, B show the average
error scores of the mice during the training. During the first 3 days
of training, GSK
+/2 mice learned to navigate to the hidden
platform and had low error scores comparable to those of WT
littermate mice (Fig. 1A). In the probe test, which was conducted
after 3 days of continuous training, GSK
+/2 mice recognized the
place where the platform used to be as well as the WT mice
(Fig. 1D). However, with more than 3 days of continuous training
(9 days of training), GSK
+/2 mice took longer than WT mice to
locate the hidden platform. Their error scores increased, while the
error scores of WT mice decreased steadily, indicating that the
WT mice had effectively learned the location of the platform
during the additional training days (Fig. 1B). To evaluate the
spatial memory of GSK
+/2 mice, we conducted a probe test 24 h
after the last session on the ninth training day. In the probe test,
GSK
+/2 mice did not show statistically significant place
preference (Fig. 1E). However, GSK
+/2 mice that received 3
days of training (Fig. 1E) and WT mice that received 9 days of
training (Fig. 1F) did show significant place preference. Thus,
GSK
+/2 mice failed to locate the previous location of the hidden
platform, while WT mice located the platform easily, indicating
that WT mice had retained place recognition, whereas GSK
+/2
mice did not (Fig. 1E).
After 9 days of training, we moved the hidden platform to a
quadrant opposite to that of the previous training session and
continued training the mice. As with the initial test (Fig. 1A),
GSK
+/2 mice learned the place of the relocated platform during
the first 3 days of training (Fig. 1C), showing comparable spatial
memory to that of their WT littermates (Fig. 1F). The swimming
speed (motor control ability) and thigmotaxic tendency (emotional
control ability) of GSK
+/2 and WT littermate mice on the first day
of training were not significantly different (Supporting information
Fig. S4), suggesting that motor and emotional factors could not
account for group differences in MWM performance. The
relatively wide range of ages of the mice (7–14 months) could
not account for differences in cognitive ability of WT and GSK
+/2
mice (Supporting information Fig. S5). Therefore, these results
were due to genetic differences between the mice, and suggest that,
although they retained the ability to learn, GSK
+/2 mice exhibited
retrograde amnesia with repeated training. Thus, GSK-3b
reduction does not affect the learning process but does affect the
memory maintenance system, such as memory consolidation and/
or reconsolidation.
GSK
+/2 impairs memory reconsolidation
A new memory is initially labile and becomes stabilized over
time through the process of consolidation. Once stabilized,
memory is not permanently fixed and can again become labile if
reactivated by recall, which is called reconsolidation. The
reconsolidation process is hypothesized to be necessary for
updating reactivated memories [22]. Although memory consoli-
dation and reconsolidation are thought to have distinct molecular
requirements, both require a protein synthesis-dependent process
[24–29]. To understand in which process GSK-3b is involved, we
examined GSK
+/2 mice in a CFC paradigm. GSK
+/2 and WT
littermate mice showed similar freezing times in response to the
unconditioning stimulus (US). Twenty-four hours after exposure to
the US, mice in the reconsolidation test group were placed in the
same context (conditioning stimulus; CS) again without the US to
reactivate their memory by recall. Mice in the consolidation group
did not receive memory reactivation until the test phase. On day 7,
memory performance of both the consolidation and reconsolida-
tion test groups (Fig. 2A) was examined by measuring freezing
time. In the consolidation test, GSK
+/2 and WT littermate mice
showed the same level of freezing (Fig. 2B), suggesting that GSK
+/
2 mice are not impaired in the ability to form and consolidate
memory. Furthermore, the consolidated memory is maintained for
at least 7 days. In contrast, GSK
+/2 mice showed significantly less
freezing in the reconsolidation test on day 7 compared to WT
littermate mice (Fig. 2C). Comparison of day 1 and day 7 freezing
times in the reconsolidation test (Fig. 2A) revealed that the freezing
times of GSK
+/2 mice decreased significantly from day 1 to day 7
(Fig. 2E), while those of WT littermate mice remained more or less
unchanged (Fig. 2D). These results indicate that GSK
+/2 mice
learned and that their memory stabilized over 7 days if memory
was not reactivated. However, GSK
+/2 mice failed to achieve
reconsolidation when the memory was reactivated once before
testing. Therefore, GSK
+/2 mice show retrograde amnesia in the
CFC reconsolidation test as well as in the MWM test, suggesting
that GSK
+/2 mice may have impaired memory reconsolidation.
Memory reconsolidation requires the activation of GSK-
3b
To confirm the involvement of GSK-3b in memory reconso-
lidation, we first investigated GSK-3b activity in C57BL/6J mice
during consolidation and reconsolidation in a CFC paradigm.
Recently, GSK-3b in synapses have been reported to be involved
in synaptic plasticity [20]. This prompted us to examine GSK-3b
activity in synaptic fractions from mouse hippocampus relative to
levels of phospho-Ser9 GSK-3b (Fig. 3B, C). One and twenty-four
hours after CS+US presentation, phospho-Ser9 GSK-3b levels
were reduced to about 72% of that of the control group, which did
not receive the CS+US presentation, suggesting that GSK-3b was
activated during memory consolidation. One hour after CS
presentation during the reconsolidation step, phospho-Ser9 GSK-
3b levels were further and significantly reduced to 50% of control
levels (Fig. 3A, C), suggesting that GSK-3b might be activated
during memory consolidation and an additional activation of
GSK-3b might be required during the reconsolidation process.
If this additional GSK-3b activation is involved in memory
reconsolidation, inhibition of GSK-3 might produce the same
effects on memory reconsolidation as that observed in GSK
+/2
mice. Thus, we next investigated the effect of GSK-3b inhibition
on memory maintenance by intraperitoneal injection of the GSK-
3 inhibitor AR-A014418 (30 mg/kg), followed by training on the
CFC paradigm. To confirm inhibition of GSK-3, C57BL/6J mice
were treated with the GSK-3 inhibitor before the consolidation
step or before the reconsolidation step (1 h before CS+US
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PLoS ONE | www.plosone.org 2 October 2008 | Volume 3 | Issue 10 | e3540Figure 1. Analysis of place learning and memory in GSK-3b heterozygous mice. The Morris water maze (MWM) was used to assess place
learning and memory of adult WT littermate and GSK
+/2 mice (7–14 months old). The cognitive function of 7- to 14-month-old mice did not show
age-dependent decline (Supporting information Fig. S5). Memory was assessed after 3 days of continuous training (A, D); 9 days of continuous
training (B, E); and 3 days of reversal testing following the 9-day continuous training session (C, F). Learning is expressed as error scores (A, B, C), and
memory performance is expressed as a percentage of total time spent in the target quadrant during the probe test (D, E, F). The probe test was given
on the fourth day (D, F) or tenth day (E) of the experiment (see Methods). Differences between genotypes were statistically analyzed with a two-way
ANOVA (A–C). Dwell times of GSK
+/2 and WT littermate mice spent in the target (T), adjacent (A), and opposite (O) quadrants were statistically
analyzed by one-way ANOVA (d–f). Results are expressed as means6SEM.
doi:10.1371/journal.pone.0003540.g001
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PLoS ONE | www.plosone.org 3 October 2008 | Volume 3 | Issue 10 | e3540Figure 2. Memory consolidation and reconsolidation in GSK-3b heterozygous mice. Memory consolidation and reconsolidation were
assessed with a contextual fear-conditioning (CFC) test following the schedule shown in A. Mice were placed in a novel environment (plastic
chamber) for 5 min (conditioning stimulus, CS), where they received three electrical foot shocks (unconditioning stimulus, US; shock
intensity=0.5 mV; duration=2 sec; inter-stimuli interval=60 sec). In the consolidation test performed 7 days later, the mice (WT littermates,
n=13; GSK
+/2, n=14; 7–14 months old) were placed into the plastic chamber again for 5 min without receiving stimulation, and freezing time was
measured (A, B). In the reconsolidation test performed on day 1 and day 7 of training, the mice (WT littermates, n=17; GSK
+/2, n=11) were placed
into the plastic chamber again for 5 min without receiving stimulation, and freezing time was measured (A, C–E). On day 7 of the consolidation test
(B), the freezing times of WT littermate (white bar) and GSK
+/2 (black bar) mice were not significantly different (p=0.437, Mann-Whitney test).
However, on day 7 of the reconsolidation test, the freezing times of GSK
+/2 mice had decreased significantly compared to that of their WT littermates
(c; p=0.0026, Mann-Whitney test). Comparison of day 1 and day 7 freezing times of WT littermate (D) and GSK
+/2 (E) mice revealed that, on day 7 of
the reconsolidation test, GSK
+/2 mice showed significantly reduced freezing times (p=0.0095, Mann-Whitney test), while WT littermate mice did not
(p.0.0733, Mann-Whitney test). Results are expressed as means6SEM; **, p,0.01.
doi:10.1371/journal.pone.0003540.g002
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PLoS ONE | www.plosone.org 4 October 2008 | Volume 3 | Issue 10 | e3540Figure 3. Memory reconsolidation requires GSK-3b activation. C57BL/6J mice (7 months old) received contextual fear conditioning according
to the test schedule shown in A. Hippocampal GSK-3b levels were then assessed at different times during the testing. One and twenty-four hours
after the presentation of paired conditioned and unconditioned stimuli (CS+US), mice were killed and phospho-Ser9 GSK-3b and total GSK-3b levels
in hippocampal synaptic fractions were analyzed by Western blotting (B, C). GSK-3b was found in the synaptic (S) fraction (B). Mice showed reduced
phospho-Ser9 GSK-3b levels after learning and during consolidation and reconsolidation compared to levels measured during ‘‘no learning’’ (C; upper
panel). Ratios of phospho-Ser9 GSK-3b-to-total GSK-3b levels, which reflect the inhibition of GSK-3b activity, are shown in the histogram of panel of C.
GSK-3b activity after learning (n=5) and during consolidation (n=5) was significantly increased compared to activity measured in the ‘‘no learning’’
group (n=7). Further significant GSK-3b activation was seen in the reconsolidation group (n=4). Statistical analysis was performed using the Tukey’s
multiple comparison test after one-way ANOVA; *, p,0.05; **, p,0.01; ***, p,0.001. Effects of a GSK-3 inhibitor on memory consolidation and
Memory Maintenance and GSK-3b
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presentation in the reconsolidation test, respectively; Fig. 3D).
The GSK-3 inhibitor reduced tau phosphorylation by 70%
compared to the vehicle control, suggesting that the treatment
inhibited GSK-3 activity (see Supporting information Fig. S6).
Inhibiting GSK-3 before the consolidation step did not impair
memory consolidation (Fig. 3E), but GSK-3 inhibition applied
before the reconsolidation step significantly impaired memory
reconsolidation (Fig. 3F). Thus, the memory reconsolidation step is
more sensitive to GSK-3b activity than the memory consolidation
step, and these results indicate that activation of GSK-3b might be
required for memory reconsolidation.
Discussion
The genetic reduction of GSK-3b and the pharmacological
inhibition of GSK-3 impaired reconsolidation of hippocampus-
dependent place memory, as demonstrated in the CFC test, a test
that assesses hippocampus-mediated memory consolidation and
reconsolidation. Hence, GSK-3b may be involved in memory
reconsolidation in the hippocampus. The mechanism of memory
formation and maintenance in the hippocampus, however, may
also involve coordinated activity in other brain regions. Clearly,
more work is needed to clarify the role of GSK-3b in cortex and
other brain regions.
Although mice expressing the dominant negative form of GSK-
3 display neuronal damage in striatum and cortex accompanied by
impaired limb mobility [30], GSK
+/2 mice did not display these
phenomena. This discrepancy may due to GSK-3a activity.
Although GSK
+/2 reduces GSK-3b activity without affecting
GSK-3a, dominant negative GSK-3 reduces both GSK-3a and
GSK-3b activity in striatum and cortex. This reduction may cause
neuronal vulnerability.
Both place learning in the MWM and context learning in the
CFC paradigm reflect mainly hippocampal-dependent learning
and memory. GSK
+/2 mice showed retrograde amnesia in the
MWM and CFC paradigms. Using the CFC paradigm, we
demonstrated that GSK
+/2, or pharmacological inhibition of
GSK-3, impaired memory reconsolidation without affecting
memory consolidation. Therefore, GSK
+/2 mice—in which
GSK-3b is genetically reduced—and WT mice treated with a
GSK-3 inhibitor lose their ability to reconsolidate memory.
Injecting a protein synthesis inhibitor (anisomycin) into dorsal
hippocampus inhibits memory consolidation and reconsolidation
in both place and context learning [31–33]. Thus, if GSK-3b is
involved in a common mechanism of memory reconsolidation
shared by both tasks, we would expect that the genetic reduction of
GSK-3b to also impair memory reconsolidation of affected mice.
Indeed, GSK
+/2 mice did display impaired memory reconsolida-
tion in both MWM and CFC tests.
During the first 3 days of training, GSK
+/2 mice did not exhibit
memory impairment (Fig. 1D). However, after 9 days of repetitive
training, GSK
+/2 mice exhibited retrograde amnesia (Fig. 1E).
Artinian and colleagues [31] found that injecting anisomycin into
CA3 after a single reactivation, inhibited memory reconsolidation
following 4 sessions of three trials in one day in a place-learning
version of the MWM paradigm. In our MWM training protocol,
mice were repeatedly trained three trials everyday. The strength of
memory in each day in our MWM protocol seems to be weaker
than that in Artinians’ protocol. The temporal dynamics of
memory reconsolidation depend on the strength and age of the
memory, such that younger and weaker memories are more easily
reconsolidated than older and stronger ones [34]. Therefore, more
than three days of repetitive training may be required for
inhibiting memory reconsolidation by genetic reduction of GSK-
3b (GSK
+/2) under our MWM protocol.
One caveat in interpreting a retrograde amnesia effect inthe CFC
paradigm is the possibility of extinction of the conditioned response,
because retrograde amnesia in repeated exposure to the same
context without reinforcement can produce extinction. Therefore, it
is possible that GSK-3b inhibition-induced retrograde amnesia may
be due to facilitation of extinction or impairment of reconsolidation.
However, the facilitation-of-extinction notion cannot explain the
result showing that GSK
+/2 mice displayed retrograde amnesia
upon repetitive training in the MWM. Since maintenance of spatial
memory in the MWM requires memory consolidation and
reconsolidation [27] and since MWM training is performed under
the existence of a reinforcer, spatial memory may not be affected by
memory extinction. Therefore, retrograde amnesia related to GSK-
3b inhibition could be due to an impairment of memory
reconsolidation, not to facilitation of extinction.
NMDA-induced bidirectional synaptic plasticity (long term
potentiation, LTP; long term depression, LTD) is believed to
underlie memory formation [35]. During LTP, neurons store
relevant information by synaptic tagging, which is thought to
underlie a stable memory trace [36]. Recently, GSK-3b activation
has been reported to be required for NMDA-dependent LTD
induction [20]. Furthermore, overexpression of GSK-3b inhibits
LTP induction [37]. Therefore, GSK-3b could modulate the
balancing of LTP and LTD in an activity-dependent manner.
Overexpression of GSK-3b impairs acquisition of reference
memory in a novel object recognition task [38]. As we have
shown in this report, the inhibition of GSK-3b blocks memory
reconsolidation but not memory acquisition or consolidation.
These observations suggest that activated GSK-3b may contribute
to memory reconsolidation by controlling LTP/LTD balance.
If LTP and LTD contribute to the formation and maintenance of
memory traces, memory acquisition and consolidation processes
may preferentially depend on LTP. In the case of memory
reconsolidation, LTD may be more important for maintaining a
prior potentiated circuit by competitive synaptic maintenance [39].
GSK-3b activation may help protect a stable memory trace from
corruption through additional synaptic connections or changes
during recall and reconsolidation. Although this idea may be
supported by the observation that greater activation of GSK-3b is
required in the reconsolidation process rather than in the
consolidation process, more precise mechanisms need to be clarified.
GSK-3b is involved in NFT formation in AD. During normal
aging, NFTs are observed in the entorhinal cortex. This may
represent a very early pathological change of sporadic AD.
Because memory reconsolidation is required for GSK-3b
activation, tau might be hyperphosphorylated when memory is
reconsolidation (D–F). Times at which mice received an intraperitoneal injection of GSK-3 inhibitor and the task schedule for contextual fear
conditioning are shown in D. Four groups of C57BL/6J mice were intraperitoneally injected with either GSK-3 inhibitor (AR-A014418; 30 mg/kg) or
vehicle solution (approximately 100 ml of 10% DMSO/40% PEG solution for each animal) 1 h before consolidation (vehicle, n=8; inhibitor, n=8) or
reconsolidation (vehicle, n=8; inhibitor, n=9). On day 7, memory performance was assessed by measuring freezing times under CS conditions. GSK-3
inhibitor administered before conditioning did not significantly affect memory performance on day 7 (E; p=0.798, Mann-Whitney test). In contrast,
when GSK-3 inhibitor was administered before reconsolidation, on day 7 freezing times of GSK-3 inhibitor-treated mice were significantly less than
those of vehicle-treated mice (F; p=0.036, Mann-Whitney test). Results are expressed as means6SEM; *, p,0.05.
doi:10.1371/journal.pone.0003540.g003
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hyperphosphorylated tau impairs learning and memory during old
age [40]. Therefore, frequent activation of memory reconsolida-
tion in older brains may damage learning and memory through
the hyperphosphorylation of tau. Thus, GSK-3b does have an
important role in memory maintenance in the adult brain, but it
may also cause NFT formation in the aged brain.
Materials and Methods
Animals
Male C57/BL6J mice aged ,7 months were used for all
experiments. Male GSK
+/2 mice (7–14 months) were maintained
by backcrossing with C57/BL6J mice. Mice were individually
housed and kept on a 12-h light/dark schedule. All mice had free
access to food and water. To assess GSK-3b activation during
memory consolidation and reconsolidation, we subjected C57BL/
6J mice to a CFC paradigm. At the indicated time points shown in
Fig. 3a, mice were killed by cervical dislocation and their
hippocampi were removed and prepared for biochemical analysis
of GSK-3b. All experiments were performed according to
procedures approved by the Animal Experiments Committee of
the Institute of Physical and Chemical Research (RIKEN).
Antibodies
We used the following antibodies: rabbit polyclonal anti-GSK-
3, mouse monoclonal anti-GSK-3b (Transduction Lab, Inc.);
rabbit polyclonal anti-phospho-Ser9 GSK-3b (Cell Signaling
Technology, Inc.).
Western blotting
Mouse hippocampi were homogenized in Tris-buffered saline
(TBS; 10 mM Tris, 150 mM NaCl [pH 7.4]) containing protease
inhibitors (1 mg/ml antipine, 5 mg/ml pepstatin, 5 mg/ml leupep-
tin, 2 mg/ml aprotinin, and 0.5 mM 4-(2-aminoethyl)benzenesul-
fonyl fluoride hydrochloride) and phosphatase inhibitors (1 mM
NaF, 0.4 mM Na3VO4, and 0.5 mM okadaic acid). After
centrifugation at 27,000 g for 20 min, the supernatant was
collected. TBS-soluble materials were solubilized in Laemmli
sample buffer and subjected to SDS-PAGE. Next, we purified
synaptic fractions from hippocampus. Hippocampi from mouse
brains were homogenized in 8 volumes of 10 mM HEPES buffer
containing protease inhibitors and phosphatase inhibitors, 5 mM
EDTA, and 300 mM sucrose, and centrifuged at 12,000 g for
10 min. The supernatant was centrifuged at 39,800 g for 40 min,
and the nuclear fraction was completely removed. The synaptic
fraction was purified from the supernatant by centrifugation at
120,000 g for 40 min. The cytoplasmic fraction was obtained by
centrifugation at 260,000 g for 2 h. Synaptic and cytoplasmic
fractions were subjected to SDS-PAGE, and separated proteins were
blotted onto nitrocellulose membranes (Schleicher & Schuell
Bioscience). The membranes were then incubated with primary
antibody, followed by the species-appropriate HRP-conjugated
secondary antibody. Chemiluminescent detection (ECL; GE
Healthcare Bio Science) was used for visualization. Quantitation
and visual analysis of immunoreactivity were performed with a
computer-linked LAS-3000 Bio-Imaging Analyzer System (Fujifilm).
Morris water maze test
To assess place learning and memory performance of mice, we
used a cylindrical test apparatus (1 m in diameter) and task closely
fashioned after the Morris water maze according to our previous
report [35]. To assess learning, for each mouse we calculated the
distance between the mouse and the platform every 0.5 sec until
the mouse reached the platform. Next, we calculated the total
distance traveled by the mouse as it searched for the platform. This
error score was used as a measure of learning performance. Lower
scores indicated better learning and memory. Each mouse was
subjected to three learning trials per day for nine successive days.
A single probe test was given on the tenth day, in which the
platform was removed from the maze in the mouse’s absence. The
mouse was introduced into the maze as before and allowed to
search for the missing platform for 60 sec. The percentage of time
the mouse spent searching in each quadrant was used as an index
of memory performance. Statistical analyses were conducted using
PRISM4 (GraphPad Software Inc.). Data were analyzed using the
Friedman test or two-way ANOVA, unless noted otherwise.
Contextual fear-conditioning (CFC) test for memory
consolidation and reconsolidation
To test the effect of GSK-3b reduction on memory consolida-
tion and reconsolidation, GSK
+/2 mice and GSK-3 inhibitor-
treated C57BL/6J mice were randomly selected and assessed on a
CFC test. The test apparatus consisted of a 60 cm640 cm640 cm
sound-proof box containing a 10 cm610 cm610 cm transparent
plastic chamber with a steel grid floor (for delivering electrical foot
shocks) and a CCD camera. To examine memory consolidation,
we exposed individual to the novel environment (plastic chamber)
for 5 min (conditioning stimulus, CS), and then delivered three
sequential foot shocks (unconditioning stimulus, US; shock intensi-
ty=0.5 mV; duration=2 sec; inter-stimuli interval=60 sec). Seven
days after CS presentation, conditioned animals were re-exposed to
thesameplasticchamberfor4 min,andfreezingtimewasmeasured
with custom software based on Matlab (version 7.2, Mathworks Co.
Ltd.). To examine memory reconsolidation, we exposed mice to the
environmental CS for 5 min. One day after CS presentation,
conditioned animals were exposed to the same plastic chamber for
4 min,andfreezingtimewasmonitoredasbefore.Sixdaysafterfirst
being exposed to the same plastic chamber, mice were re-exposed to
the chamber, and memory reconsolidation was assessed by
measuring freezing time. The same behavioral analyses were
applied in experiments testing the affect of GSK-3 inhibition on
C57BL/6J mice and biochemical analysis of GSK-3b activity
during contextual fear conditioning.
Supporting Information
Figure S1 Generation of GSK-3b heterozygote mouse. Using
homologous recombination, we flanked the exon-encoding
catalytic domain of GSK-3b with loxP elements. Floxed GSK-
3b mice were crossed with mice expressing Cre recombinase
under the control of the EIIa promoter, and their progeny were
crossed with C57/BL6J mice (A). The offspring of this latter cross
underwent PCR tail DNA analysis using the primer sets indicated,
and mice harboring the delta allele were selected (B). The brains of
six wild-type (GSK-3b+/+; WT littermate) and six heterozygous
(GSK-3b+/2; GSK+/2) mice were homogenized and GSK-3a
and GSK-3b expression levels were examined by Western blotting
(C). GSK-3b (D) and GSK-3{lwoer case alpha} (F) expression
levels were quantified with a computer-linked LAS-3000 Bio-
Imaging Analyzer System. Although there were no significant
differences in the GSK-3a expression levels of WT and GSK+/2
mice (n=6, p=0.1797, Mann-Whitney test), the GSK-3b
expression levels of GSK+/2 mice were about 50% of that of
the WT littermates (n=6, p=0.0022, Mann-Whitney test).
Reduced GSK-3b activity in GSK+/2 mice was confirmed by
incorporating radiolabeled 32P into GSK-3 substrate peptide (E)
(n=6, p=0.0022, Mann-Whitney test). Results are expressed as
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amount (C, E) and relative activity (F) of GSK-3b in GSK+/2
mice were approximately 50% and 70%, respectively, of those in
WT littermates. The total amount and relative activity of GSK-3a,
a homologue of GSK-3b, in GSK+/2 mice were similar to those
in WT mice (C, D). Consistent with a previously report [20], our
GSK+/2 mice were healthy, fertile, and showed no changes in
circadian rhythm, life span, motor control, and locomotor activity
compared to WT mice (see Supporting information Fig. S2).
GSK+/2 mice, however, displayed reduced GSK-3b activity,
without showing GSK-3a compensation.
Found at: doi:10.1371/journal.pone.0003540.s001 (0.13 MB PDF)
Figure S2 Basic characteristics (circadian rhythm, locomotor
activity, motor control activity, and life span) of GSK+/2 mice.
GSK+/2 mice showed similar awake/rest patterns as WT
littermate mice when housed under 12-h light/dark conditions
(A). After measuring the locomotor activity of three GSK+/2 and
three WT mice for 3 successive days under home-cage conditions,
we found that the total daily locomotor activity (number of beam
crossings) of GSK+/2 mice during circadian monitoring did not
significantly differ from that of WT littermate mice (B). Motor
control activity (C) was tested using an accelerated rotarod test
(1.5–15 rpm/3 min). GSK+/2 and WT littermate mice did not
show significant motor-skill differences (Mann-Whitney test).
Furthermore, GSK+/2 and WT littermate mice showed
comparable survival times (D) (Log-rank test, p.0.05).
Found at: doi:10.1371/journal.pone.0003540.s002 (0.11 MB PDF)
Figure S3 Path length (A) and latency (B) of WT and GSK+/2
mice in the MWM during 9 days of training. During the first 3
days of training, both WT and GSK+/2 mice showed reduced
latency to platform and shorter path-length to platform after
repetitive training. After longer, subsequent training, WT mice
showed reduced latency to platform and shorter path-length to
platform, but GSK+/2 mice did not. This tendency is similarly
reflected in the error score plot of Fig. 1B. Because the error score
is a value representing the cumulative distance a mouse travels to
find the platform during each trial, the error score not only reflects
a mouse’s path-length information during training but also it also
reflects a mouse’s trace information until it reaches the platform.
Found at: doi:10.1371/journal.pone.0003540.s003 (0.08 MB PDF)
Figure S4 The emotional responses of GSK+/2 mice to the
Morris water maze were determined by assessing swim speed (A)
and thigmotaxis tendency (B). In this analysis, we used only data
obtained from the first training day to omit the influence of
learning. Both emotional parameters indicated that no significant
differences exist between GSK+/2 (n=19) and WT littermate
(n=20) mice (p.0.05, Mann-Whitney test).
Found at: doi:10.1371/journal.pone.0003540.s004 (0.05 MB PDF)
Figure S5 The effect of aging on place memory formation was
investigated by comparing probe test scores (percentage of stay time
in the target quadrant) after 9 days of training (Fig. 1E). Three age
groups (7–9 months, 10–11 months, 12–14 months) of WT and
GSK+/2 mice were assessed. Although the relatively wide range of
ages, 7–14 months, did not affect place memory formation (two-way
ANOVA analysis; aging factor, F=0.4772,p=14.86), genotype,
WT vs. GSK+/2, did formation (two-way ANOVA analysis;
genotype factor, F=6.020,p=0.0196).
Found at: doi:10.1371/journal.pone.0003540.s005 (0.08 MB PDF)
Figure S6 AR-A014418 inhibited tau phosphorylation, as
shown in the Western blots probed with TauC, a phosphorylation
independent anti-tau antibody; PHF1 (generously provided by Dr.
Peter Davies, Albert Einstein College of Medicine, NY), a
phosphorylation-dependent anti-tau antibody; and Tau1 (CHE-
MICON, Temecula, CA), a non-phosphorylation-dependent anti-
tau antibody, which recognizes non-phosphorylated Ser199 and
Ser202. AR-A014418 reduced tau phosphorylation (PHF1
immunoreactivity was reduced, Tau1 immunoreactivity was
increased, TauC immunoreactivity was unchanged) to 70% of
that produced by vehicle injection alone, suggesting that
peripheral treatment with a GSK-3 inhibitor inhibited GSK-3
activity by 30%.
Found at: doi:10.1371/journal.pone.0003540.s006 (0.08 MB PDF)
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